ReCerise Therapeutics Inc. ("ReCerise"), a company committed to research and development of first-in-class therapeutics in oncology, recently entered a research partnership with the National Cancer ...

Hepatocellular carcinoma continues to pose a diagnostic challenge, particularly in the setting of underlying pathomorphological changes in the liver due to cirrhosis, steatosis, or steatohepatitis.

ReCerise Therapeutics Inc. ("ReCerise"), a company committed to research and development of first-in-class therapeutics in oncology, recently entered a research partnership with the National Cancer ...

A groundbreaking cancer study led by Professor Tom Bird from the Cancer Research UK Scotland Institute has discovered a drug ...

This study investigated the long-term prognosis and clinical course of patients who survived for more than 5 years after hepatocellular carcinoma (HCC) diagnosis.This retrospective cohort study used ...

SBRT improved local progression-free survival over RFA in small recurrent HCC, particularly in tumors 2 cm or less.

A mother of three who died days after receiving a liver cancer diagnosis is a tragically common case, a charity has said.

A man living with advanced liver cancer has seen his tumour shrink by over half as “exciting” new clinical trials are ...

A MUM tragically died just days after doctors found her ‘food poisoning’ was actually one of the UK’s deadliest cancers. Sian ...

A 35-year-old woman thought she had food poisoning, but it turned out to be terminal cancer. Her tragic death will raise ...

BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESRE ...